Health systems are not stepping into artificial intelligence from a place of calm or control. In the United States, spending now exceeds $4.5 trillion, with a significant share tied up in administrative work that adds complexity more than clarity. Clinicians are caring for more patients, navigating more data and making more decisions under pressure than ever before. The system is stretched. Artificial intelligence is entering at a moment when change is no longer a choice.

The discussion drew on the experience of three leaders who are not observing this shift. They are guiding it. Hal Wolf leads HIMSS, influencing digital health policy and implementation across more than 100 countries. Isaac Kohane, MD, PhD, Chair of Biomedical Informatics at Harvard Medical School, has spent four decades defining how data informs clinical care. Ran Balicer, MD, Chief Innovation Officer at Clalit Health Services, operates within one of the world’s most integrated health systems, where data and care are aligned across generations.

These are not just star panelists. They are system-wide architects.  What emerged from the hour-long conversation was not what artificial intelligence can do. It was a recognition that it is already doing more than most systems are prepared to guide and govern.

Dr. Kohane captured the tension immediately. “I think that we have to worry about the fact that we’re going both too slow and too fast.”

That statement reflects a reality many leaders feel but rarely express. Governance takes time because it must. Patient safety, validation and accountability require structure. Practice moves in real time. Clinicians do not have the luxury of waiting for perfect systems.

“They’re so desperate to do right by their patients to use other resources,” Dr. Kohane adds.

That instinct is not a weakness. It reflects a commitment to doing what is right for the patient. When clinicians turn to external AI tools, they are seeking clarity, speed, and confidence in their decisions. Artificial intelligence is already present at the point of care, shaping how physicians assess information, validate thinking, and move forward. The system is not adopting AI. The system is catching up.

This creates a condition that is difficult to measure and even harder to manage. Different clinicians use different ChatGPT platforms. Those tools produce different answers. Different assumptions shape those answers. Over time, consistency erodes. The system begins to operate with multiple definitions of truth (and the risk of varied outcomes).

Dr. Kohane’s warning is not about misuse. It is about misguided permanence. “The worst outcome will be if the worst parts of medicine get concrete poured over it, by AI.”

Artificial intelligence does not fix a system; without leadership, it accelerates the integration of incorrect assumptions. If workflows are inefficient, they become more efficiently inefficient. If bias exists in data, it becomes more precise. If fragmentation defines care, it scales.

This is not a failure of technology. It is a mirror held up to system-wide leadership.

Hal Wolf, among the health sector’s leading policy and operational voices, grounded this moment in proven experience. Health care has seen this pattern before. When internet connectivity entered hospitals, clinicians moved faster than governance. They created access where it was needed. Systems responded later. Risks were discovered after adoption.

Artificial intelligence now follows that same trajectory, though at far greater speed and with far greater consequences. Web connectivity gave quick access to information. Artificial intelligence influences how that information is interpreted and acted upon.

“We have to go faster,” Mr. Wolf said. “But there needs to be structure around it.”

That is the leadership challenge of this moment. Speed without structure creates exposure. Structure without speed creates irrelevance. The tension between the two is not something to resolve. It is something to manage continuously.

The industry has predictably responded to artificial intelligence. It has started where risk is lowest and return is clearest. Documentation, scheduling and revenue cycle optimization have become the entry points. These applications reduce burden and improve efficiency. They are necessary. However, they are not transformational.

The shift occurs when artificial intelligence moves into clinical decision-making. At that point, the question is no longer whether the system works. The question becomes whether it should be trusted.

Who owns a decision informed by an algorithm? How is accuracy validated? What happens when a clinician disagrees with a recommendation? These are not technical questions. They are questions of accountability. Artificial intelligence does not assume responsibility. It does not carry consequence. That remains with leadership.

Dr. Balicer reframed the conversation, shifting how the room thought about artificial intelligence. “There’s no such thing as AI neutrality. Algorithms are just opinions embedded in code.”

That insight is easy to acknowledge and difficult to operationalize. Every model reflects choices. What data is included? What outcomes are prioritized? What trade-offs are accepted? Those decisions are embedded in the system, shaping how it interprets information.

When a health system adopts an AI tool, it is not simply implementing technology. It is adopting a perspective.

At Clalit Health Services, alignment across payer and provider creates a system where priorities are consistent. Even there, external AI models introduce new assumptions. Those assumptions may not align with the system’s goals. If leadership does not define its own values, it inherits someone else’s.

This becomes real in proactive care. Artificial intelligence enables systems to identify patients at risk before they present. It allows for earlier intervention, often improving outcomes.

It also creates a new kind of pressure. “The toughest choice is what not to do,” Dr. Balicer said.

That statement deserves more attention than it receives. Health care has been built around responding to need. Artificial intelligence introduces the ability to anticipate it. When every patient can be flagged, every risk predicted and every intervention suggested, the system is no longer constrained by insight. It is constrained by capacity.

Artificial intelligence expands what can be done. It does not expand who can do it. Leadership becomes the act of choosing who does what based on validated data.

There is a moment that captures this shift. Imagine a primary care physician starting the day not with a schedule of patients who have called for appointments, but with a list generated by AI identifying individuals who are likely to experience clinical complications in the next six months. Some will develop chronic conditions. Some will require hospitalization. Some can be helped now – preventively.

The physician cannot see them all. Artificial intelligence expands what is possible. Leadership decides what is essential and permissible.

The industry often responds to complexity with activity. Organizations pilot, test and explore. They engage broadly without committing deeply. This creates motion. It rarely creates progress. Pilots are nothing more than experiments. At some point, leadership must decide what to scale, what to stop and what defines value.

Hal Wolf grounded the conversation in discipline. Without a defined, shared objective, effort becomes noise. Pilots create learning, though they often avoid decision-making. Leadership requires clarity. What problem are we solving? What outcome defines success? What are we willing to prioritize? Without those answers, artificial intelligence adds another layer of complexity to an already complex system.

Dr. Kohane brought the conversation back to the discipline of leadership. It cannot remain abstract. It must be informed by experience.

“Go and pay a few bucks and use three or four of the models… get a feel for what this does,” Dr. Kohane advised.

That is not a call for technical fluency. It is a call for leadership proximity. Leaders cannot guide what they do not understand. Artificial intelligence does not behave consistently across models. It produces different answers, shaped by different assumptions. Without direct engagement, those differences remain hidden, and leadership becomes removed from the very decisions it is responsible for guiding.

This is where many organizations hesitate. Artificial intelligence feels complex and complexity invites delegation. At this moment, delegation creates distance. Leadership is required to move closer, not further away.

Artificial intelligence is not reducing the role of leadership. It is redefining it.

This is not a gradual transition. It is already underway. Artificial intelligence is embedded in workflows, shaping decisions and influencing behavior in real time. The system is adapting whether leadership is ready or not.

The question is no longer whether artificial intelligence will shape the future of health. It will. The question is whether leadership will shape how it is applied.

Artificial intelligence will not fix health. It will scale whatever we allow it to touch. The question is whether it will scale what is best in health or what we have yet to fix.

The post AI Will Not Fix Health Care – Leadership Might appeared first on Medika Life.

This is the hidden reality shaping patient care today. A life-saving treatment has little meaning if it is not within reach when a patient needs it.

Zebra Technologies’ recent hospital vision study brings this issue into sharp focus by examining materials management across health systems. The findings reveal that patient outcomes are influenced by clinical expertise and operational readiness. Nearly three-quarters of hospital leaders report that procedures or surgeries have been delayed or canceled because necessary supplies or equipment were unavailable. Each statistic reflects not an abstract system failure, but a human experience marked by anxiety, disruption, and risk.

Access the survey here.

“At Zebra, we remain closely attuned to the needs of the healthcare market. Our findings indicate that a significant majority of non-clinical leaders, 84%, consider the integration of automated, digital systems for tracking all materials used in patient care to be a key initiative for their organizations,” commented Boyede Sobitan, Global Healthcare Strategy Lead at Zebra Technologies.

In most industries, “stockouts” are a consumer inconvenience. In health, it carries far greater consequences. The absence of medication, a device, or equipment can alter the trajectory of care. It can delay treatment, extend suffering, or force clinicians into difficult compromises. The implications reach beyond logistics into the realm of patient safety, trust and survival.

This reality calls for a broader understanding of how care is delivered. Health care is often framed as a relationship between patient and clinician. That relationship remains central, yet it exists within a larger ecosystem. Supply chain leaders, inventory specialists and operational teams play a defining role in whether care can be delivered as intended. The Zebra study notes that 84 percent of decision-makers recognize that inventory management directly affects patient safety. This acknowledgment signals an important shift in thinking.

Care mat begins at the bedside, but the infrastructure that ensures continued implementation begins much earlier, in the systems that ensure readiness.

One of the more revealing insights from the study concerns something deceptively simple: language. Hospitals often lack a shared definition of what it means for an item to be out of stock. For some, it may indicate that inventory has dropped below a threshold. For others, it may mean that an item is unavailable in a specific department, even if it exists elsewhere in the system. This inconsistency creates confusion, delays response, and limits the ability to anticipate problems before they escalate.

Communication failures in health care are frequently associated with clinical interactions. This study highlights that operational communication is equally important. When teams lack a shared understanding, coordination suffers. When coordination suffers, patient care is affected.

“It’s essential that hospital teams have real-time visibility into the location and condition of their most vital resources, and we are observing a clear trend of accelerated investment in technologies that provide both location awareness and automation,” adds Zebra’s Sobitan.

The challenge is compounded by fragmentation across systems. Hospitals have invested significantly in digital tools, from electronic health records to procurement platforms. These investments have improved individual functions, yet they often operate in isolation. Data resides in separate systems. Visibility is incomplete. Teams spend valuable time searching for information or confirming availability.

This fragmentation introduces inefficiencies that extend beyond cost. It places additional strain on clinicians who must navigate uncertainty while maintaining focus on patient care. It also contributes to burnout in a workforce already managing intense demands. Time spent searching for equipment or resolving supply issues is time taken away from direct patient interaction.

There is, however, a clear path forward. The study points to a growing adoption of digital inventory management systems that bring greater standardization and visibility to supply chains. These systems create a shared source of truth, allowing teams across departments to access consistent, real-time information. When inventory levels are transparent and definitions are aligned, organizations can shift from reactive responses to proactive management.

This transition represents more than a technological upgrade. It reflects a cultural shift toward integration and collaboration. When data is accessible and consistent, decisions become more informed and more timely. When teams operate from the same understanding, coordination improves. The result is a system better equipped to support clinicians and patients alike.

It is tempting to view materials management as a background function, separate from the clinical mission. The findings suggest otherwise. Inventory is not peripheral to care delivery. It is foundational to it. Without reliable access to supplies and equipment, even the most advanced clinical capabilities cannot be fully realized.

This perspective reframes the role of operational teams within healthcare. Their work creates the conditions for care to occur. It supports clinicians by removing barriers and reducing uncertainty. It strengthens the system’s ability to deliver on its promises to patients.

At its core, this issue is about trust. Patients enter health-delivery settings with the expectation that the system is prepared for them. Providers rely on that same expectation as they make decisions and deliver care. When supplies are unavailable or systems are fragmented, that trust is tested. When readiness is consistent and reliable, trust is reinforced.

The future of health will continue to be shaped by scientific discovery and technological innovation. Those advances must be matched by equal attention to the operational readiness that enables their delivery. Investment in supply chain visibility, data integration, and operational alignment is not separate from the mission of care. It is integral to it.

Health leaders have an opportunity to rethink what constitutes innovation. It includes not only what is developed in laboratories or deployed in operating rooms, but also what ensures that those advancements reach patients without delay or disruption. Elevating materials management to a strategic priority reflects a commitment to reliability, safety, and patient-centered care.

A quiet transformation is underway in how healthcare systems approach this challenge. It is visible in efforts to standardize processes, integrate data, and connect teams across traditional boundaries. It may not generate headlines, yet its impact is profound.

The most advanced health system is defined by the skill of its patient-facing staff, the sophistication of its treatments, and its readiness to deliver care. It ensures that when a patient needs care, every piece of the operational puzzle is in place to provide it.

That readiness often goes unnoticed when it functions well. Its absence, however, is immediately felt.

The post The Invisible Lifeline: Why Supplies, Not Just Science, Determine Patient Care appeared first on Medika Life.

History, however, offers a useful caution. Breakthrough technologies in medicine rarely achieve their full potential simply because they exist. Their real impact depends on whether the institutions responsible for health-care delivery know how to adopt them wisely, integrate them responsibly and align them with their mission to improve patient health.

Artificial intelligence now stands at that same threshold. The industry has moved beyond fascination with what algorithms can do and entered a more demanding phase: determining how these tools should be evaluated, governed, and integrated into the environments where care is delivered. At the same time, some health professionals are turning to AI – not to augment their knowledge – but assuming the information is patient-care ready.

Across the health ecosystem, leaders are discovering that the most important questions about artificial intelligence are not technological. They are organizational, ethical and operational. Which AI systems genuinely improve clinical decision-making? Which tools strengthen the efficiency of hospitals and health systems? Which innovations introduce complexity without delivering measurable benefit?

Answering those questions requires a perspective that bridges policy leadership, real-world care delivery, and the scientific foundations of biomedical informatics. That convergence of experience sits at the center of a “Views From the Top” mainstage discussion at the HIMSS Global Health Conference & Exhibition, where some 35,000 leaders whose work spans the global health ecosystem will examine how organizations can recognize the true value proposition of artificial intelligence applications before embedding them into health-care systems.

The perspectives shaping this discussion reflect three essential dimensions of responsible artificial intelligence in health: governance frameworks that guide innovation, operational insights from large-scale health care delivery, and scientific rigor grounded in biomedical informatics. Together, these vantage points illuminate the path from technological promise to practical value.

Governing Innovation in a Rapidly Changing Health Ecosystem

Digital transformation in health rarely succeeds simply because technology exists. It succeeds when organizations develop leadership frameworks capable of evaluating innovation, managing risk and aligning new tools with patient-centered goals.

Few leaders have observed the evolution of digital health across as many national systems and institutional environments as Hal Wolf, president and chief executive officer of HIMSS, Ran Balicer, MD, PhD, chief innovation officer of Clalit Health Services and Isaac Kohane, MD, PhD, chair of biomedical informatics at Harvard Medical School. The three will step onto the mainstage at HIMSS to share their “View from the Top” in a session titled: “Recognizing the ‘Value Proposition’ Criteria While Selecting AI Applications.”

Through his work with global government health ministries, hospital networks, and technology innovators worldwide, Wolf has consistently emphasized that technological progress must be anchored in governance and trust.

“Digital health transformation is not about technology alone. It is about leadership, governance, and the trust that allows innovation to improve care,” Wolf has said in discussions about global digital health transformation.

Artificial intelligence intensifies this leadership challenge because its influence extends far beyond traditional clinical tools. AI systems increasingly operate across multiple layers of healthcare delivery. Some applications assist clinicians by analyzing medical data or suggesting treatment options. Others function within hospitals’ and health systems’ operational infrastructure, helping manage patient flow, prioritize diagnostic reviews, and allocate scarce resources.

These operational algorithms rarely capture headlines; however,  they shape the environment in which health care is delivered. Decisions about which cases are reviewed first, how clinicians allocate their attention, and how health systems manage capacity can profoundly influence patient outcomes.

For leaders responsible for health systems, artificial intelligence cannot be treated as simply another technological upgrade. It must be evaluated through governance structures capable of understanding how algorithms function, what assumptions shape their recommendations, and how their use aligns with institutional priorities.

Without that oversight, innovation risks amplifying complexity rather than improving care. Instead of informing, it can spread misinformation.

Aligning Artificial Intelligence With the Values of Medicine

Governance provides the policy foundation for responsible adoption of artificial intelligence, but real-world implementation reveals a second challenge: ensuring that AI systems operate effectively within healthcare delivery itself.

Large population health systems increasingly use advanced analytics to anticipate risk, manage chronic disease, and allocate clinical resources across diverse communities. Within these environments, artificial intelligence is no longer a theoretical innovation. It is already influencing how health organizations prioritize patients, coordinate care and deploy limited resources.

That operational perspective is central to Ran Balicer, MD, PhD, of Clalit Health Services, one of the world’s most advanced data-driven health systems. The Clalit integrated infrastructure connects hospitals, clinics, and community health programs through longitudinal datasets that support predictive analytics at the national scale.

Experience within such systems reinforces an important insight: artificial intelligence models do not function independently of human judgment. They reflect priorities embedded in their design and the assumptions guiding their deployment.

“Algorithms are opinions embedded in code,” Balicer has observed in discussions about the role of artificial intelligence in population health.

In practice, this means that AI systems interpret clinical data through frameworks shaped by human choices. The way a model defines risk, prioritizes cases, or recommends interventions reflects decisions about what matters most within a healthcare environment.

Those decisions carry ethical implications. When artificial intelligence helps determine which patients receive immediate attention or which cases are escalated for further review, transparency about how algorithms function becomes essential to maintaining trust among clinicians and patients alike. The scientific frontier of health-care AI reinforces that concern.

Isaac Kohane, MD, PhD, who has also served as a co-author of the Institute of Medicine Report on Precision Medicine, which has served as the template for national efforts, has spent decades exploring how machine learning can advance medicine while preserving the judgment that defines clinical practice. His research emphasizes that artificial intelligence in healthcare must align with the ethical traditions and professional responsibilities of medicine.

“AI systems in medicine must ultimately reflect the values of the profession they serve,” Kohane has written in discussions about AI alignment in biomedical informatics.

This perspective highlights a crucial distinction between technological capability and clinical responsibility. Many AI models entering healthcare environments were originally designed for broader computational tasks rather than the nuanced realities of patient care. Medicine operates within a landscape shaped by uncertainty, empathy, and accountability, and technologies introduced into that environment must reflect those values.

Ensuring that artificial intelligence aligns with the principles guiding health-care delivery, therefore, represents one of the most important scientific and ethical challenges facing the future of health.

The Discipline Required to Make Innovation Matter

The health sector has experienced waves of technological enthusiasm before. Electronic health records promised seamless information exchange, but then introduced administrative burdens on health professionals when implemented without thoughtful workflow design. Data analytics promised unprecedented insight, but sometimes led to fragmentation when systems failed to communicate across institutions.

Artificial intelligence now stands at a similar moment in the evolution of health technology.

Its capabilities in supporting decision-making flow are extraordinary, yet realizing them will require disciplined leadership to evaluate, integrate and govern AI tools within health-care delivery systems. Health leaders must learn to ask deeper questions before embracing the next algorithmic breakthrough. What problem does this system truly solve? How does it strengthen clinical practice? What assumptions guide its recommendations? How does its use advance the mission of improving patient health?

These questions move the conversation beyond technological novelty toward operational practicality. It’s among the many reasons these three global leaders step to the HIMSS stage together.

Artificial intelligence will undoubtedly reshape the health ecosystem in the years ahead. Its long-term impact, however, will not be determined solely by the sophistication of algorithms or the speed of technological progress. Along with how to leverage AI, ChatGPT and LLMs, users require heightened cognitive awareness.

It will be determined by whether the health community develops the discipline and ability required to translate innovation into systems that strengthen care, support clinicians and improve the health of the populations they serve.

The real story of artificial intelligence in health is no longer about what machines can do. It is about how wisely the health sector chooses to use them.

The post From AI Excitement to Execution: Why Health Leaders Must Now Master the “How” appeared first on Medika Life.

Scientific Promise and Practical Benefits

A major strength of brain organoid research is its potential to improve our understanding of neurological and psychiatric conditions. Researchers can generate organoids from people with known genetic mutations to study how specific genes affect early brain development. This method has been used to study conditions like autism spectrum disorders, epilepsy, schizophrenia, and Alzheimer’s disease. It helps scientists find cell abnormalities that might not show up in animal studies.

Brain organoids are also useful for drug discovery and safety testing. Many treatments that work in animal models do not succeed in humans, especially for brain disorders. Organoids give scientists a human-based way to test how drugs affect neural cells. This can help spot toxic effects or benefits earlier, potentially lowering the risk of expensive late-stage failures and reducing unnecessary testing on people.

Limitations, Misconceptions, and Ethical Concerns

Even though brain organoids show promise, they have important limitations that are sometimes missed in public discussions. They lack blood vessels, immune cells, and sensory input, all of which are needed for normal brain function. Because they lack a vascular system, organoids obtain oxygen and nutrients only by diffusion, which limits how large and mature they can become. Most organoids end up looking like early fetal brain tissue, not fully developed brains. Does the appearance of something mean it will have the same abilities?

Variability is another challenge. Organoids grown in different laboratories — or even within the same lab — can vary in structure and cellular composition. This makes standardization difficult and complicates the interpretation of results. Additionally, reports of electrical activity within organoids have sometimes been mischaracterized as evidence of consciousness. Most neuroscientists agree that current organoids do not possess awareness, sensation, or thought, but the debate highlights broader uncertainties about how consciousness arises in biological systems.

As the science has advanced, ethical questions have also increased. There are concerns about informed consent when donor cells are used to make neural tissue, especially if donors did not know this could happen. Other worries come up when human organoids are put into animals, which raises questions about species boundaries and oversight. Although these experiments are closely regulated, many ethicists say clearer rules are needed as the technology develops.

Future Directions and Responsible Progress

Researchers are now trying to make brain organoids more realistic and useful. They are working on adding vascular-like systems, combining different organoid types to study how brain regions interact, and making results more consistent between labs. These improvements could help us better understand complex brain disorders and lead to more personalized treatments.

At the same time, ethical guidelines are changing to keep up with new scientific advances. Many experts say that as organoid research moves forward, it should be matched by openness, oversight from different fields, and regular public involvement. Brain organoids are not miracle cures or major threats; they are powerful but imperfect tools that can help neuroscience when used carefully. The future of this research will depend on both technical progress and a strong focus on ethics and public trust.

If all of this sounds like something from a Frankenstein movie, that would be one approach to take, but it isn’t realistic. We are only at the very beginning of understanding what the potential and the problems involved are for us. The research holds great promise, but it also requires informed restrictions that will not prevent advances.

The post Brain Organoids: Promise, Limits, and What Comes Next appeared first on Medika Life.

Primary care continuity allows physicians to develop a longitudinal awareness that no episodic encounter or health tech tool can replicate. Over time, physicians learn what is normal for each patient and what represents meaningful clinical change. Subtle physiological shifts, early symptoms or emerging risk factors appear not as isolated data points from a blood exam, but as part of a social narrative unfolding across time. Early recognition allows earlier intervention, often before disease takes its profound toll.

Clinical evidence confirms the protective effect of continuity. It’s not a matter of opinion. A systematic review published in BMJ Open found that patients with sustained continuity of care had significantly lower mortality than those with fragmented care. Continuity did not just improve satisfaction; it altered survival. The physician who knows the patient can detect disease earlier and guide care more effectively.

Listening allows physicians to detect patterns that laboratory values alone cannot explain. Patients share information differently when they believe that their physician understands them and remembers their history. This sustained awareness allows physicians to identify emerging illnesses without relying solely on reactive diagnostics. Continuity transforms listening into clinical intelligence and a deeper care partnership.

In Healing the Sick Care System: Why People Matter, which has become a surprise Amazon bestseller, one insight repeatedly emerges: patients do not seek care only for treatment; they seek reassurance that someone who knows them is guiding their journey. Physicians who listen across time accumulate knowledge that cannot be captured in a chart alone. That memory allows earlier recognition, more accurate interpretation, and wiser intervention. Healing begins in that continuity of understanding.

Transactional Care Solves Symptoms but Sacrifices Understanding

Health has, for some time, been undergoing a structural shift toward transactional encounters. Walk-in clinics, urgent care centers, and virtual platforms provide speed and accessibility that patients value. These models address immediate symptoms efficiently and fill important gaps in care delivery. Accessibility has improved, yet continuity has weakened.

Transactional medicine treats episodes rather than trajectories. Each encounter begins without the benefit of longitudinal understanding. Clinical decisions are made with time-stamp specific knowledge of how symptoms emerged or how physiology has changed over time. Care becomes reactive rather than interpretive.

Research demonstrates the consequences of this fragmentation. Studies published in the Annals of Family Medicine show that sustained primary care continuity reduces hospitalizations and lowers healthcare expenditures. Early recognition prevents complications that require more invasive, costly interventions. Fragmentation delays recognition and increases clinical risk.

In fact, physicians in the vanguard of building relationships encourage their patients to ask questions.  In their co-authored book Let Patients Help! A “Patient Engagement” handbook – how doctors, nurses, patients and caregivers can partner for better care by “e-Patient Dave” deBronkart with Daniel Z. Sands, MD, MPH, the founder of the Society for Participatory Medicine, offer 10 suggestions that clinicians say to encourage patient engagement.

This shift also alters how patients engage with care. Connections that develop over time can be lost quickly when continuity disappears. Patients become consumers navigating isolated services rather than partners guided across time. The clinical relationship weakens, and with it the interpretive depth that makes prevention possible.

Health systems globally recognize the value of continuity. The Organization for Economic Co-operation and Development (OECD), a Paris-based international organization that promotes policies to improve economic and social well-being globally, reports that hospital admissions for chronic diseases, often preventable through effective primary care, account for a substantial share of healthcare utilization. Systems that preserve physician-led primary care continuity achieve better outcomes and greater efficiency. Relationship stabilizes care.

Innovation Requires Connection to Fulfill Its Potential

This shift toward transactional care carries life-threatening implications that extend far beyond the patient experience. It also directly affects whether health innovation fulfills its promise or becomes a compensatory tool addressing fragmentation. Innovation depends on context to generate meaningful insight. Context emerges through continuity. That context can devalue life-saving innovations.

Artificial intelligence, predictive analytics, and remote monitoring technologies are designed to detect patterns across time. These tools require longitudinal clinical awareness to distinguish meaningful change from statistical variation. Physicians who know their patients can interpret innovation correctly and act earlier. Innovation becomes transformative when anchored in relationship.

Fragmented care weakens this interpretive capacity. Data collected across disconnected encounters lacks coherence. Predictive tools lose precision when longitudinal context is absent. Innovation becomes reactive, identifying disease after symptoms emerge rather than predicting disease before it develops.

Technology achieves its highest value when it extends the physician’s ability to listen and observe. Remote monitoring allows earlier recognition of physiological change. Predictive analytics strengthens preventive intervention. Innovation amplifies continuity when guided by sustained physician leadership.

Team-based primary care models reflect this principle. Nurse practitioners and physician assistants expand access while physician leadership preserves interpretive continuity. Research published in Medical Care Research and Review confirms that coordinated team-based care maintains strong clinical outcomes. Physician oversight ensures that innovation remains integrated within longitudinal care. It also improves health professional job satisfaction and reduces burn-out.

Innovation cannot replace the relationship at the center of medicine. Algorithms detect patterns but do not understand meaning, and they do not strengthen physician/patient ties. Devices collect data, but do not know the patient behind the data. Physicians translate information into guidance by integrating technology with human understanding.

The future of health innovation depends on preserving continuity between patient and physician. Technology deployed within sustained relationships strengthens prevention and improves outcomes. Technology deployed within fragmented systems often compensates for structural weakness rather than transforming care. Continuity determines whether innovation fulfills its promise.

Health systems now face a defining moment. Transactional care offers speed and convenience. Relational care offers understanding and prevention. Innovation will achieve its full potential only when it strengthens the continuity that allows physicians to listen, learn, and guide patients across time.

Healing begins with being heard. Health technology succeeds when it helps physicians listen more deeply and act more wisely in the service of the people who entrust them with their care.

The post How Transactional Medicine Threatens the Future of Your Health appeared first on Medika Life.

The country’s trajectory has been building for years. A fast-growing middle-income population, rising chronic disease burden, and expanding health infrastructure have created both demand and urgency. What is changing now is the environment in which innovation can move, driving faster approvals, a culture of collaboration, digital infrastructure and a government signaling policy readiness to engage global partners in shaping the next era of medicine.

The economic momentum is significant. The Indian health ecosystem has expanded from roughly $372 billion in 2023 to $638 billion in 2025, making it one of the fastest-growing major health markets in the world. The broader industry is expected to exceed $610 billion by 2026, fueled by rising insurance coverage, expanding hospital infrastructure, and growing demand for chronic disease management. Health growth in India continues at approximately 10–12 percent annually, well above the growth rates typical of mature markets, reflecting both rising access and structural transformation.

BIOAsia 2026 reflects this inflection point. The global gathering in Hyderabad, themed “TechBio Unleashed: AI, Automation & the Biology Revolution,” highlights the (bio)convergence of biology, data, and intelligent systems reshaping health worldwide. Organizers emphasize that the meeting aims to drive health transformation and reinforce India’s position as a leading global life sciences force. For multinational innovators, the message is increasingly clear: India is not only where innovation is deployed; it is also where it is developed. It is where innovation is increasingly defined. India has become a go-to market for multinational enterprises.

Policy Signals and Market Scale: From Opportunity to Strategic Partnership

India’s regulatory and policy environment is evolving in ways that matter deeply to multinational innovators. One pivotal shift came with the country’s decision to allow certain medicines approved in specified developed markets to launch without local clinical trials, a move designed to accelerate patient access while aligning more closely with global regulatory science. This policy shift reflected confidence in international data, a commitment to innovation, and recognition that faster access must remain central to national health strategy.

The scale of India’s pharmaceutical and life sciences market reinforces this transformation. The pharmaceutical sector reached approximately $68 billion in 2025 and is projected to grow to more than $170 billion during the next decade, driven by expanding middle-income demand and strong domestic manufacturing. India already supplies roughly one-fifth of the world’s generic medicines. It produces the majority of global vaccines by volume, positioning the country as a central player in global health supply chains.

As Aman Gupta of SPAG/FINN wrote in Medika Life, “India’s health sector is undergoing a profound transformation, bolstered by government-led reforms and a favorable FDI regime. The allowance of 100% foreign direct investment through automatic routes in health and related sectors has already attracted global giants.” His observation reinforces a central reality for multinational innovators: India’s policy environment is increasingly designed not only to welcome global participation, but to encourage long-term strategic partnership in building the future of healthcare.

Investment trends tell the same story. Health and pharmaceutical private equity and venture investments have reached multi-billion-dollar levels annually. At the same time, India’s contract drug development and manufacturing sector is projected to exceed $22 billion within the next decade. These dynamics position India as a growth market and as a strategic partner across the innovation lifecycle from discovery and clinical development to manufacturing and global distribution.

Shakthi Nagappan, CEO of Telangana Life Sciences Foundation, captured this moment clearly, noting that BIOAsia arrives at a time when technology and biology are redefining healthcare and creating “unprecedented opportunities for innovation, investment, and impact.” The language reflects partnership rather than transaction, a signal that India is moving from market opportunity to strategic collaboration.

Digital Infrastructure, BIOAsia and the Multinational Innovation Imperative

India’s digital transformation may be its most potent catalyst for long-term health innovation. Unlike many mature systems, the country is building a national-scale digital health infrastructure designed to connect patients, providers, and health systems across a population of more than 1.4 billion people, with a rising middle class of 400 million.

The Global Digital Health Market is projected to grow from USD 288.55 billion in 2024 to USD 2,688 billion by 2035, expanding at a CAGR of 22.55% during 2025–2035. This surge is driven by the rapid adoption of AI-powered diagnostics, telemedicine, wearable devices, and data analytics solutions that are revolutionizing patient care and operational efficiency worldwide.

Hundreds of millions of citizens are already using digital health services, including telemedicine, electronic prescriptions, and remote care. The Ayushman Bharat Digital Mission is creating an interoperable national health ecosystem, enabling secure health records, improved care coordination, and population-scale data infrastructure that supports research, real-world evidence, and precision health.

For multinational companies, this digital backbone creates a uniquely strategic environment, enabling large-scale clinical research, faster pharmacovigilance, AI-supported health insights, and rapid deployment of innovation across diverse populations. India’s digital infrastructure is not simply modernizing health delivery. It is enabling national-scale transformation.

BIOAsia sits at the center of this conversation and convergence. The gathering reflects India’s ambition to lead at the intersection of biology, artificial intelligence, and scalable innovation. Leaders from industry, government, and science convene not only to discuss growth but to shape the next phase of global life sciences, where biology, data, and digital systems converge to influence global health.

One conference panel, among the many high-powered sessions, brings together global leaders in advanced therapeutics to explore how next-generation modalities are moving from discovery to scalable care. Panelists across biopharma, translational science, and hospital systems are examining progress in cell and gene therapies, mRNA, and radiopharmaceuticals, underscoring that innovation now depends as much on manufacturable scale and delivery as on scientific breakthrough. India’s expanding capabilities in clinical research and bioprocessing strengthen its role as a key partner in advancing next-generation therapies.

For multinational innovators, the implications are clear. Engagement in India now extends beyond commercialization. It calls for collaboration in research, investment in digital and scientific ecosystems, alignment with national health priorities and partnership in strengthening health delivery.

India’s Strategic Role in Global Health Innovation

India’s rise in global health innovation reflects the alignment of policy, market growth, digital infrastructure, and scientific capability forces that together are reshaping where and how healthcare innovation occurs.

For multinational companies, India now represents a full-spectrum innovation environment. It is a place to conduct clinical research across diverse populations, scale manufacturing and supply chains, deploy digital health at a national scale, and co-develop solutions addressing both local and global health challenges. Increasingly, India is not simply a recipient of innovation developed elsewhere. It is becoming a co-creator of next-generation health.

This shift changes the strategic equation. Market entry alone is no longer sufficient. Meaningful engagement requires partnership with policymakers, regulators, scientists, health providers, and digital health ecosystems. Organizations that invest in collaboration, align with national health priorities, and contribute to strengthening healthcare systems are most likely to succeed in India’s evolving landscape.

BIOAsia sets the stage for this transformation. It is more than a conference. It is a convergence of global health ambition, scientific capability, and policy momentum. The conversations taking place in Hyderabad mirror a broader reality: the geography of health innovation is expanding, and India is now central to its future.

For global health innovators, the question is no longer whether India matters. The question is how deeply they choose to engage in shaping what comes next.

The post India: The Growing Focal Point for Health Innovation appeared first on Medika Life.

In later life, weight loss can be a double‑edged sword. A few pounds off the joints can be both helpful and risky. Shedding a few pounds may ease joint pain, but losing weight without meaning to can be a warning sign. Fast weight loss can also lead to muscle loss, which is key to staying independent.

Experts also point out practical issues: injections need good vision, steady hands, and a regular routine. Stomach and bowel side effects can be tougher for seniors, especially if they’re already losing weight without trying. complicate life for older adults — and how to approach them with a “safety first” mindset.

1) Aging changes the risk–benefit math (even when a drug “works”)

Older adults, especially those who are frail or have several health issues, are often left out of clinical trials. This is important because average trial results may not match the real-life experience of a 75-year-old who takes several medications and needs to manage appetite and hydration.

A 2024 debate paper on GLP-1 drugs in older patients, including those with kidney disease, points out that limited trial data and multiple medications make it harder to judge safety and effectiveness for frailer seniors. Clinicians need to make decisions based on each person, not just on averages. In simple terms, the real question is not whether GLP-1s are good or bad, but whether they help this specific older person with their unique health needs.

There’s another subtle issue: in later life, the goal is often less about chasing an ideal weight and more about protecting function—walking safely, rising from a chair, maintaining balance, staying hydrated, and maintaining enough strength to live independently. So for older adults, the most important question isn’t “How much weight will I lose?” It’s “What will this do to my strength, my nutrition, and my ability to stay steady on my feet?”

2) Common side effects can become serious for older adults.

GLP-1s often cause nausea, vomiting, diarrhea, constipation, and less appetite. Younger people may find these symptoms unpleasant but manageable. For older adults, though, these issues can quickly lead to dehydration, dizziness, and falls, especially if they also take blood pressure medicines or diuretics.

Current FDA labeling for semaglutide products highlights this pathway: stomach and bowel side effects can lead to volume depletion, and acute kidney injury has occurred, including in postmarketing reports. The label advises monitoring kidney function when starting or increasing doses in people who develop severe gastrointestinal reactions, and it notes that dehydration has been part of reported kidney injury cases.

This is how many real-life problems start: a few days of not being able to eat or drink much, then feeling lightheaded, falling, or needing emergency care for dehydration. Older adults may not feel as thirsty and may have less ability to recover. So, it’s important to watch hydration, electrolytes, blood pressure, and kidney function, especially in the first months of treatment and after increasing the dose.

3) Muscle and frailty: losing weight does not always mean better health.

The headline benefits of GLP‑1s often focus on pounds lost. But the body doesn’t lose only fat. Lean mass (including muscle) can drop, too. This matters in older adults because age‑related muscle loss (sarcopenia) is already common — and it’s tightly linked to frailty, falls, and loss of independence.

A 2025 mini-review on older adults warns that starting and stopping GLP-1s repeatedly can change body composition, sometimes leading to ‘sarcopenic obesity’ — having too much fat and too little muscle. The authors are not saying to avoid GLP-1s, but to remember that weight loss does not always mean better health for older people.

More pointedly, a 24‑month retrospective cohort study in older adults with type 2 diabetes reported that semaglutide use was associated with muscle loss and functional decline, particularly at higher doses and in patients who already had sarcopenia. The authors emphasize individualized risk–benefit assessment and the need for monitoring and intervention.

If you’re reading this as an older adult, it may help to translate the research into plain questions to bring to your next appointment: “If I lose weight, how will we protect my muscles?” “How will we check whether I’m getting weaker?” “What would make us stop or change course?” An older adult who becomes “smaller but weaker” has not gained health — only risk.

4) Other complications: gallbladder, pancreas, vision, and low blood sugar

Gallbladder and bile duct problems can be an unexpected issue. Losing weight already increases the risk of gallstones, and GLP-1s seem to increase it even further. A large review found that using GLP-1 drugs increases the chance of gallbladder or bile duct disease, especially at higher doses, for longer periods, or when used for weight loss.

For older adults, this might present as sudden pain in the upper right side of the belly, nausea, fever, or pain spreading to the back or shoulder. These symptoms should be checked by a physician right away.

GLP-1 drug labels also warn about the risk of sudden pancreatitis and say to get medical help for severe, ongoing belly pain. The overall risk is low, but older adults may have additional risk factors, such as gallstones or high triglycerides. Severe belly pain in later life should always be checked quickly.

Then there’s the risk of blood sugar dropping too low. GLP‑1s don’t usually cause hypoglycemia by themselves, but the risk rises when combined with insulin or sulfonylureas. Semaglutide labeling warns that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia and may require dose reductions of those agents.

In older adults, hypoglycemia can be particularly dangerous: it can cause falls, confusion, fainting, and cardiac stress. It’s also easier to miss, because symptoms may look like “just being tired” or “a little off today,” especially in someone who already has memory or balance problems.

Eyes and vision deserve special attention. Semaglutide labeling includes a warning about diabetic retinopathy complications and recommends monitoring patients with a history of retinopathy. Beyond labeling, post‑marketing safety monitoring continues to explore visual signals.

A 2025 analysis of FDA adverse event reporting data found a potentially elevated risk of vision‑impairment reports with semaglutide use compared with some other diabetes and weight‑loss medications, and it called for vigilant surveillance and further research. That doesn’t prove the drug causes vision loss in an individual patient, but it is enough to justify a cautious posture: new blurring, blind spots, or sudden changes deserve a same‑week medical call, not a “let’s see if it passes.”

5) Surgery and sedation: delayed stomach emptying can cause problems

GLP‑1 medications slow stomach emptying — one reason people feel full sooner. But that same effect can complicate anesthesia and deep sedation if food remains in the stomach despite standard fasting. A 2024 review describes the connection between GLP‑1 medications, delayed gastric emptying (including gastroparesis), and increased risk of aspiration during anesthesia, as well as possible effects on the absorption of other medications.

This issue has become important enough that several medical groups have created guidelines for surgery. The 2024 guidance says many people can continue taking GLP-1s, but doctors should look for higher-risk situations, such as people with stomach problems or other risks of food entering the lungs, and adjust plans as needed.

This is important for older adults because they are more likely to undergo procedures requiring sedation, such as colonoscopies, joint injections, cardiac procedures, dental work, or surgeries. The easiest and most often missed safety step is to tell every physician involved — surgeon, anesthesiologist, endoscopist, dentist — that you are taking a GLP-1 medication and when you last took it. Do not assume it will be clear in your medical chart.

6) A senior‑friendly “yes, with a plan” approach

If you’re an older adult considering a GLP‑1 (or already taking one), a safer approach often looks like “yes, with monitoring.” That means starting with function, not just the scale: tracking energy, steadiness, and strength in everyday life, not only pounds.

It also means treating hydration as a real medical concern. Ongoing nausea, vomiting, or diarrhea is not just part of getting used to the medicine. These symptoms can affect blood pressure and kidney function, especially when changing doses.

Because muscle matters so much in later life, protecting it should be part of the prescription. That can include discussing protein intake, adding a realistic strength plan (even chair‑based work or physical‑therapy guided resistance), and reassessing the medication if weight loss is accompanied by weakness, poor balance, or reduced stamina.

Older adults should also have their medications reviewed with a focus on preventing low blood sugar. If insulin or a sulfonylurea is being used, doses may need to be adjusted as appetite decreases and blood sugar improves.

Finally, it is important to take symptoms seriously. New stomach pain, ongoing vomiting, or sudden vision changes should be checked by a doctor right away. Before any procedure with anesthesia or deep sedation, make sure to tell the medical team about your GLP-1 use — do not assume they already know.

The GLP-1 medications can help some older adults, but there is less room for mistakes. Side effects can quickly lead to dehydration, frailty, falls, or problems during procedures. The safest approach is not just ‘yes’ or ‘no,’ but ‘yes, with a plan’ — one that protects hydration, nutrition, muscle, vision, and safety during medical care.

The post GLP‑1 Medications in Later Life: Why the “Miracle Shot” Needs a Senior‑Specific Safety Lens appeared first on Medika Life.

I have spent more than 30 years in healthcare with one consistent mission: helping people sustain and improve their lives. That mission has guided my work across large pharmaceutical companies, entrepreneurial startups, and academic institutions. It has shaped how I view innovation—not as a luxury, but as a necessity.

We often speak about healthcare innovation as if it exists in a vacuum. It does not. Innovation only matters if patients can access it, understand it, and afford it. Today’s system too often breaks that chain.

The U.S. healthcare system has evolved to prioritize risk management over prevention, short-term cost containment over long-term health, and utilization controls over patient outcomes. The consequences are real. Breakthrough therapies are delayed or denied. Preventive medicines are underused. Patients are left navigating complexity at the very moment they are most vulnerable.

However, innovation has repeatedly proven it can change the trajectory of disease—and lives—when it reaches patients.

Earlier in my career, I had the opportunity to help build Claritin into a household name. What made Claritin transformational was not just the molecule, but access. Non-sedating allergy relief allowed people to function—to work, learn, drive, and live daily life without compromise. We paired scientific innovation with brand-building, education, and emerging digital tools to enable patients to engage with their care in new ways. That experience taught me something enduring: innovation fails when it remains trapped behind complexity.

As digital channels emerged, I saw how virtual access could democratize care. Early online refill capabilities and digital front doors were not about marketing. They were about meeting patients where they were. Innovation is not only what happens in the lab; it is how solutions are delivered in the real world.

More recently, my work in cardiovascular and preventive medicine has reinforced this belief. Cardiovascular disease remains the leading cause of death globally, yet preventive innovation often struggles most to gain access. When therapies reduce future heart attacks, strokes, and hospitalizations—but do not show immediate cost offsets within narrow budget windows—they face resistance. This is actuarial logic colliding with human biology.

But prevention works. Inflammation matters. Long-term risk reduction matters. Helping people avoid catastrophic events enables them to remain productive, engaged, and present in their lives and with their families. The value of that outcome is difficult to capture on a quarterly balance sheet, but it is undeniable.

Innovation also matters because healthcare is not static. Populations are aging. Chronic disease is rising. Demand for care will only increase. Without continued pharmaceutical innovation—new mechanisms, better tolerability, improved adherence—we risk managing decline rather than enabling vitality.

Critics often frame innovation and affordability as opposing forces. They are not. The real tension lies between short-term system incentives and long-term societal benefit. When access to effective therapies is delayed or denied, costs do not disappear. They shift—reappearing as hospitalizations, disability, lost productivity, and diminished quality of life.

I have worked inside large organizations, small startups, and everything in between. I have seen how difficult it is to bring a medicine from concept to patient—and how fragile that final step of access can be. That is why innovation must be paired with thoughtful policy, modernized reimbursement, and a patient-centered view of value.

Healthcare should not be about simply surviving longer. It should be about living better for longer. Medical innovation, particularly in pharmaceuticals, plays a central role in making that possible. Even in a system burdened by complexity and constraints, innovation remains one of our strongest tools for advancing healthcare.

After three decades, my belief has not changed: when science, access, and mission align, lives improve. That is worth fighting to achieve.

The post Medical Innovation Still Matters—Even When the System Makes It Hard appeared first on Medika Life.

These innovations promise earlier diagnosis, greater precision and improved efficiency by augmenting the knowledge and insight that health professionals develop through years of care. Yet beneath this progress lies a more difficult question. Will we use technology to strengthen the physician–patient relationship, or allow it to redefine the nature of care?

As written in Healing the Sick Care System: Why People Matter, “…the system is not broken because it lacks innovation, talent, or investment, but because it has lost sight of the people it exists to serve.” Technology is not the epicenter of care. It is meant to support communication, deepen relationships, and strengthen the human bond at the center of medicine.

Yet as artificial intelligence becomes embedded in diagnostics, decision support, documentation, reimbursement and care navigation, extraordinary clinical potential is accompanied by a growing tension.

Two Encounters, One Technology

For instance, in a primary care practice, a physician begins a routine visit with a patient in their mid-50s who has diabetes and hypertension. An ambient AI system seamlessly documents conversations, captures symptoms, updates medications, and generates a clinical note. The physician no longer turns toward a screen. Connection with the patient is essential. The patient speaks openly about fatigue, stress, and concern about long-term health.

Midway through the visit, the electronic record surfaces an AI-generated prompt suggesting an adjustment in therapy based on predictive risk modeling. The physician pauses, not to mindlessly follow the algorithm, but to ask additional questions about daily routine, financial constraints, and willingness to adopt lifestyle changes. Technology informs conversation. It does not replace it.

When the visit ends, documentation is complete, the treatment decision is shared, and the patient leaves with confidence, clarity and a sense of partnership in care. The physician directs the encounter. Technology supports judgment and understanding. The visit feels thoughtful, personal and grounded in relationship.

Now imagine the same technology in a different environment. The documentation remains seamless. The prompts still appear. The system functions efficiently. But here, the pace is set as much by operational demand as by clinical judgement. The schedule tightens. The visit is short. The physician moves quickly from one room to the next, guided less by the patient’s story and more by the system’s tempo. The encounter becomes transactional and compressed. Technology has not changed. What has changed is who is directing the care.

This is the quiet divide now shaping modern medicine. One path preserves physician-directed care, where technology supports human understanding. The other reflects system-directed transaction, where efficiency begins to overshadow the relationship. The difference lies not in the tool but in the priorities that shape its use.

This question of direction is not theoretical. It reflects a deeper shift in how technology may shape human judgment itself. Innovation theorist John Nosta, whose work has long been rooted in the health sector and now spans a broader landscape, cautions in his Psychology Today column: “Artificial intelligence is far from neutral, and we need to be careful by calling it simply a tool. By simulating understanding, it may reshape what humans expect from thinking itself. Over time, it can erode the habits required for discernment. And this danger is cumulative. It doesn’t announce itself as failure. It arrives as convenience.” Nosta is also the author of the upcoming book: The Borrowed Mind—Reclaiming Human Thought in the Age of AI.

When Technology Reflects the System Around It

Technology itself is not the challenge. When developed in partnership with physicians, nurses, and other health professionals, it can be transformative. Many of the most effective innovations emerge when developers observe the realities of care and design tools that strengthen human interaction rather than disrupt it.

John Whyte, MD, MPH, CEO of the American Medical Association, has emphasized that artificial intelligence must support physicians and care teams, not replace clinical judgment, and that technology should strengthen, not weaken, the physician–patient relationship.

A clear example of this tension is emerging in the context of prior authorization. Health professionals and administrative staff often spend more than a dozen hours each week navigating authorization requirements, time taken directly from patient care. New AI-enabled platforms, such as Optum’s Digital Authorization Complete powered by Humata Health, are designed to remove that burden by embedding real-time automation into clinical workflows and reducing manual steps. These innovations restore something invaluable: time.

Now, the deeper question is not technological but human. When time is returned to the system, how will it be allocated to the health professional? Will it allow clinicians to deepen their understanding of patient needs and strengthen their connection? Or will it simply enable the system to see more patients during their shift? The technology is neutral. Its meaning is shaped by people’s intent.

Health care operates within systems shaped by financial and operational pressures. In a transactionally driven environment, even well-intentioned technology can be redirected toward productivity rather than connection. A tool designed to restore time can become a mechanism to increase throughput. A system intended to support thoughtful care can accelerate volume in a fee-for-service environment. Technology inevitably reflects the values and objectives of the system in which it is deployed. It is not the technology that directs decisions and action; it’s the leadership.

The scale of investment underscores the stakes. The global AI in health market, estimated at roughly $36–39 billion in 2025, is projected to grow substantially in the coming decade. Investment shapes priorities. Priorities shape design. Design shapes experience. And experience shapes trust.

Emerging guidance aligned with the American Medical Association emphasizes that artificial intelligence must remain under meaningful clinical oversight. Technology must support physicians and care teams, not replace judgment or responsibility. Governance, transparency, and continuous evaluation are essential to ensure that technology strengthens patient safety, clinical reasoning, and trust.

This perspective aligns with participatory medicine. Dr. Danny Sands of the Society for Participatory Medicine has described health care not as a service transaction, but as a collaboration between patient and clinician. In that view, technology should support relationship-centered care, not redirect medicine toward system-driven throughput.

The Direction of Care

Health systems face real pressures: workforce shortages, clinician burnout, chronic disease, and financial strain. These realities demand smarter and more scalable solutions. Artificial intelligence offers meaningful progress. It can detect disease earlier, reduce administrative burden, and support more informed decisions. But efficiency is not healing.

Healing occurs when patients feel understood, supported, and guided by clinicians who have the time and space to listen and respond with care. When technology restores time and that time deepens connection, it fulfills its promise. When reclaimed time becomes additional volume, something essential is diminished.

Artificial intelligence will continue to shape medicine. The deeper question is not whether technology will advance, but who will decide how it is used and for what purpose.

If guided primarily by efficiency, care risks becoming faster but less human. If guided by partnership with physicians and patients, it can restore time to listen, space to understand, and the ability to decide together. Technology is not the healer. People are.

When guided by clarity of purpose, with the patient at the center of effort, and grounded in physician-guided judgment, technology becomes what it was always meant to be: a force that strengthens knowledge, deepens understanding, and restores the bond between physician and patient. Systems matter. They enable scale, coordination, and progress. Yet their purpose is fulfilled only when they serve people. Health care is at its best when human connection and well-designed systems work together in the service of healing.

The post Who Will Direct Patient Care: Physicians or Technocrats? appeared first on Medika Life.

Healthcare is no exception, and in the wake of the murder of George Floyd and the national awakening to the scourge of systemic racism in our country, more and more conversations about racism in healthcare are being had, across our country, and in the medical literature. This is only a good thing, and I hope and pray they lead to rectification of the healthcare disparities faced by people of color in this country.

One such conversation was recorded in the excellent Critical Matters podcast, hosted by Dr. Sergio Zanotti — world-renown Critical Care Medicine specialist and Chief Medical Officer for Sound Critical Care, a national critical care medicine practice. He was speaking with Dr. Greg Johnson, Sound Physicians’ Chief Medical Officer for Hospital Medicine and thought leader within his field and a champion for diversity, inclusion, and belonging within medicine.

In this episode, Dr. Zanotti and Dr. Johnson have an honest conversation about healthcare, race, and racism in healthcare. It was eye-opening, and it is a must-listen for every healthcare professional in this country. You can listen to it here:

Dr. Johnson reiterated that many Black Americans must go to great lengths to let members of the healthcare team taking care of their families know the value of their loved one: what job they do; what they mean to their families; what they mean their communities.

First of all, I was shocked by this. And yet, when I thought back to my Black patients and their families, I realized that many of them did just that: go out of their way to let me know how important this patient in front of us was to them, their family, and their community.

Just the other day, I had a husband tell me, “This woman, she is the rock of our family.” Another family member of a patient with COVID-19 told me something similar. I never paid attention to this phenomenon, and I am so very grateful I heard this conversation to open my eyes to this reality.

This is wrong. This is horrific. This is terribly sad. No one should have to justify to me why their loved one is important, how prominent their loved one is in the community. It is absolutely horrible that Dr. Tyson’s had to show the healthcare professionals taking of his father that his father was a prominent lecturer in order to garner respect from them. How can this be?

Every patient we take care of has worth, has value. Black, Brown, Yellow, Red, or White, all our patients have worth, and the fact that Black Americans feel the need to describe how important their loved ones are to get respect is truly nauseating. And you know what they are saying to us? Black Lives Matter.

Painful though it may be, it is reality, and it is of absolute importance that we in healthcare are cognizant of this reality and work to rectify it. Indeed, I told that husband that his wife has worth, and I will do all that I can to care for her within her values and wishes.

Racism in healthcare is real; it is pervasive; it is indeed a pandemic. We need to acknowledge it and then work to overcome it. All of us in healthcare have a responsibility to do what we can to achieve this end. And for starters, all of us in healthcare should listen to this conversation about racism in healthcare to understand the problem and how to fix it.

The post Every Healthcare Professional Must Listen To This Conversation appeared first on Medika Life.